Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06211374 · ClinicalTrials.gov registry record · NA
Communication Bridge Pilot Study
A NA study of Primary Progressive Aphasia, sponsored by University of Chicago.
- Active
- Registry status
- NA
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT06211374: Active NA study of Primary Progressive Aphasia, sponsored by University of Chicago.
NCT06211374 is a NA study of Primary Progressive Aphasia that is active but no longer recruiting, run by University of Chicago. The registered enrollment target is 12 participants, below the 92-participant average among 15 other Primary Progressive Aphasia trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06211374, a NA study of Primary Progressive Aphasia, is active but no longer recruiting, sponsored by University of Chicago.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this study is to evaluate the effectiveness and feasibility of evidence-based interventions in individuals living with mild to moderate primary progressive aphasia (PPA) that address communication-focused outcomes.
Primary Outcome
Goal Attainment Scaling, a 7-point rating scale with -3 representing 'no longer participating' and +3 representing 'exceeded goal'. Higher scores indicate better progress in goal achievement.
Conditions Studied
Interventions
- BEHAVIORAL Communication Bridge
Study Locations (1)
Illinois
- University of Chicago - American School Building - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2024-06-28 |
| Est. Completion | 2026-05-31 |
| Phase | NA |
What the registry record for NCT06211374 still lists
NCT06211374 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 92-participant average among 15 other Primary Progressive Aphasia trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Primary Progressive Aphasia appearing as the primary indexed condition, and to 1 intervention - of which Communication Bridge is the first listed.
NCT06211374 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT06211374 about?
NCT06211374 is a clinical study titled "Communication Bridge Pilot Study". The aim of this study is to evaluate the effectiveness and feasibility of evidence-based interventions in individuals living with mild to moderate primary progressive aphasia (PPA) that address communication-focused outcomes.
What is the current status of trial NCT06211374?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 12 participants. The study started on 2024-06-28. Estimated completion is 2026-05-31.
What conditions does trial NCT06211374 study?
This clinical trial studies the following conditions: Primary Progressive Aphasia.
What interventions are being tested in trial NCT06211374?
The interventions under investigation include: Communication Bridge (BEHAVIORAL).
Who is sponsoring clinical trial NCT06211374?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06211374 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Progressive Aphasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06211374's enrollment target sits among peer trials
12 13th of 15 higher than 2 of 15 other Primary Progressive Aphasia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Primary Progressive Aphasia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Enhancing Language Function in Aphasia
RECRUITING · NA
-
Enhancing Language Function in Primary Progressive Aphasia
RECRUITING · NA
-
Targeting Language-specific and Executive-control Networks With Transcranial Direct Current Stimulation in Logopenic Variant PPA
RECRUITING · NA
-
Cognitive Reserve and Response to Speech-Language Intervention in Bilingual Speakers With Primary Progressive Aphasia
RECRUITING · NA
-
Treating Primary Progressive Aphasia and Apraxia of Speech Using Non-invasive Brain Stimulation
ACTIVE NOT RECRUITING · NA
-
Treatment for Speech and Language in Primary Progressive Aphasia
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI